{"id":"NCT00594386","sponsor":"UCB Pharma","briefTitle":"An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease","officialTitle":"An Open-Label Extension to the Double-Blind SP650 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-08","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2008-01-15","resultsPosted":"2009-12-18","lastUpdate":"2014-10-02"},"enrollment":258,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"Rotigotine","otherNames":["Neupro"]}],"arms":[{"label":"Rotigotine","type":"EXPERIMENTAL"}],"summary":"The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease.","primaryOutcome":{"measure":"Number of Subjects With at Least One Adverse Event During This Open-label Extension Study","timeFrame":"6 years","effectByArm":[{"arm":"Rotigotine","deltaMin":258,"sd":null}],"pValues":[]},"eligibility":{"minAge":"31 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":41,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":165,"n":258},"commonTop":["Somnolence","Fall","Oedema peripheral","Nausea","Dizziness"]}}